Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
Authors
Keywords
-
Journal
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-06-10
DOI
10.1007/s00432-021-03672-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland
- (2021) J. Smith-Palmer et al. BMC CANCER
- Evaluation of 177Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors
- (2020) Estephany Abou Jokh Casas et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy
- (2020) Lisa Bodei et al. LANCET ONCOLOGY
- Retreatment with peptide receptor radionuclide therapy in patients with progressing neuroendocrine tumours: efficacy and prognostic factors for response
- (2018) Emily Vaughan et al. BRITISH JOURNAL OF RADIOLOGY
- Evaluation of clinical prognostic factors and further delineation of the effect of mesenteric fibrosis on survival in advanced midgut neuroendocrine tumours
- (2018) Faidon-Marios Laskaratos et al. NEUROENDOCRINOLOGY
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
- (2017) Jonathan Strosberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas
- (2017) Bryan Oronsky et al. NEOPLASIA
- Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
- (2017) Arvind Dasari et al. JAMA Oncology
- Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study
- (2016) Martyn E Caplin et al. ENDOCRINE-RELATED CANCER
- Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites
- (2016) Samira M. Sadowski et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic role of lactate dehydrogenase in solid tumors: A systematic review and meta-analysis of 76 studies
- (2015) Fausto Petrelli et al. ACTA ONCOLOGICA
- Bone Metastases in Well-to-Moderately Differentiated Neuroendocrine Tumors
- (2015) Juraj Kavecansky et al. PANCREAS
- Predictors of Long-Term Outcome in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
- (2014) S. Ezziddin et al. JOURNAL OF NUCLEAR MEDICINE
- Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
- (2012) H. Sorbye et al. ANNALS OF ONCOLOGY
- Usual and Unusual Neuroendocrine Tumor Metastases on 68Ga-DOTANOC PET/CT
- (2012) Niraj Naswa et al. CLINICAL NUCLEAR MEDICINE
- Chromogranin A and Neuron-Specific Enolase as Prognostic Markers in Patients with Advanced pNET Treated with Everolimus
- (2011) James C. Yao et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Serum and Ascites Chromogranin-A in Patients With Metastatic Neuroendocrine Tumors
- (2011) Richard R.P. Warner et al. PANCREAS
- Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE)
- (2010) R. Garcia-Carbonero et al. ANNALS OF ONCOLOGY
- Multimodal management of neuroendocrine liver metastases
- (2010) Andrea Frilling et al. HPB
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
- (2009) Anja Rinke et al. JOURNAL OF CLINICAL ONCOLOGY
- Small intestinal neuroendocrine tumors: Prognostic factors and survival
- (2009) Deidi Strickland Bergestuen et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States
- (2008) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search